Data as of Sep 29
| +0.01 / +0.42%|
The 2 analysts offering 12-month price forecasts for Protalix Biotherapeutics Inc have a median target of 5.75, with a high estimate of 8.00 and a low estimate of 3.50. The median estimate represents a +141.60% increase from the last price of 2.38.
The current consensus among 3 polled investment analysts is to Hold stock in Protalix Biotherapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.